Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
about
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in AdolescentsPractitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescentsCardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.Attention-Deficit Hyperactivity Disorder and Long-QT Syndrome: Risky BusinessLong-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.Lobeline Effects on Cognitive Performance in Adult ADHD.Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.Does childhood attention-deficit/hyperactivity disorder predict risk-taking and medical illnesses in adulthood?Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale.Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.Developments and challenges in the diagnosis and treatment of ADHD.Managing the risks of ADHD treatments.Aortic dissection in children and adolescents with Turner syndrome: risk factors and management recommendations.Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes.Hypertension in Young People: Epidemiology, Diagnostic Assessment and Therapeutic Approach.Primary Pediatric Care Psychopharmacology: Focus on Medications for ADHD, Depression, and Anxiety.An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder.Attention deficit-hyperactivity disorder is associated with reduced blood pressure and serum vitamin D levels: results from the nationwide German Health Interview and Examination Survey for Children and Adolescents (KiGGS).Cardiac autonomic dysfunction and arterial stiffness among children and adolescents with attention deficit hyperactivity disorder treated with stimulants.Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorderUpdates on treatment of attention-deficit/hyperactivity disorder: facts, comments, and ethical considerations.Ambulatory Blood Pressure Monitoring in a Cohort of Children Referred with Suspected Hypertension: Characteristics of Children with and without Attention Deficit Hyperactivity Disorder.Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.Cardiac reactivity and stimulant use in adolescents with autism spectrum disorders with comorbid ADHD versus ADHD.
P2860
Q22241419-43CF8DBB-ECFF-4E92-A148-D487057C081CQ28282770-C8DF2C73-8D68-498A-9BD3-39F28340DEF6Q30399107-074F551F-E79B-4B6E-9185-97F6066680E9Q33165891-25FCE934-7C51-4442-91A1-5136B2E6DBF1Q33165982-A18A0B4F-DC80-4EE0-8455-3575882851AEQ33774323-B6773367-64E2-42E4-A897-6B241F516F6FQ34362939-CE4C4E92-93D8-4C63-A19C-F09DDAAF2A10Q34461113-EDE343C7-43F4-46F7-87CD-EE36CDF1BBA0Q36321595-0D8B606F-41B2-420B-ABE6-237AC8B3F6A2Q36871524-2BEED4F0-9E5A-4199-B785-9650F5BEA688Q37190637-B99B3025-3D08-4C5F-80ED-3390186BB965Q38011640-E1C71F15-8A80-40C7-99C8-EF96840F9A9AQ38154181-43343D16-1256-40CC-8918-19B9A3C65F4CQ38241131-AD1350C8-C9DC-4597-8D45-C8A4916F6BC5Q38312457-B7B75099-9A50-4425-8C7C-8E16905D92EEQ38389306-7A08EEE8-AC3E-4861-BC1B-BAC137B700D5Q38537323-E89CB718-C235-4EC4-B513-4E46958E4EC8Q38543795-910ADC61-6B52-45E8-AD67-BDC0CAA1B706Q39043925-2D866A53-BA92-4565-8154-1C7EF4B04DC5Q39170905-C7426147-A964-4E96-9F48-B91898145F86Q39621300-832A4354-1740-4F4D-AC47-58558CD1A799Q39752543-6EF1EF0B-6009-4ADA-AC06-FA9141F51701Q40207017-67DC1955-C1D7-4716-9088-0B4FB58FFC8BQ40654140-DA6DAE72-6313-4BE0-A354-1D009B4A5019Q41473870-EFC40740-4815-4213-83F6-EF095A99004AQ41900772-89DC28E2-3512-4D7F-BAF8-B7039B961B68Q47677209-FBC7A286-ECBB-4B6E-B078-709FA66E73D9Q50310728-9D63B201-4372-46E3-8E57-434307D08459
P2860
Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cardiovascular risk of stimula ...... and clinical recommendations.
@en
Cardiovascular risk of stimula ...... and clinical recommendations.
@nl
type
label
Cardiovascular risk of stimula ...... and clinical recommendations.
@en
Cardiovascular risk of stimula ...... and clinical recommendations.
@nl
prefLabel
Cardiovascular risk of stimula ...... and clinical recommendations.
@en
Cardiovascular risk of stimula ...... and clinical recommendations.
@nl
P2093
P921
P1476
Cardiovascular risk of stimula ...... and clinical recommendations.
@en
P2093
Paul G Hammerness
Rachel Shelley-Abrahamson
Timothy E Wilens
P304
P356
10.1016/J.JAAC.2011.07.018
P577
2011-09-03T00:00:00Z